astrazeneca oral glp 1 divulges new GLP-1R agonists AstraZeneca (AZN) Advances Oral GLP-1

Sept 11: Israelbased BioLineRx won FDA approval for Aphexda (motixafortide), a stem cell mobilization agent for patients with multiple myeloma scheduled for autologous stem cell transplantation (ASCT)

Liraglutide modulates gut Microbiome and attenuates nonalcoholic fatty liver in db/db mice

Your semaglutide diet plan to minimize muscle loss should include: Adequate protein intake

Additional cardiovascular outcomes trials for other GLP-1 receptor agonists are in progress, and results are anticipated in the near future

10.1002/jbmr.2564 Summary Keywords glucagonlike peptide1 receptor agonist, randomized controlled trial, older adults, bone mineral density, bone turnover Citation Dinkla L, Beavers KM, Robbins R, Akpalu D, Wherry SJ, Miller G, Beavers DP, Espinoza S, Trejo J, Stepanenko A and Cortes TM (2025) Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis